Patents Examined by Barry A Chestnut
  • Patent number: 12290561
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: May 6, 2025
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan
  • Patent number: 12280103
    Abstract: The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
    Type: Grant
    Filed: June 5, 2022
    Date of Patent: April 22, 2025
    Assignee: Sichuan Clover Biopharmaceuticals, Inc.
    Inventors: Peng Liang, Joshua Liang
  • Patent number: 12280100
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Grant
    Filed: December 21, 2023
    Date of Patent: April 22, 2025
    Assignee: Children's Hospital Medical Center
    Inventors: Karnail Singh, Paul Spearman
  • Patent number: 12281307
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: April 22, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hassan Javanbakht, Søren Ottosen, Morten Lindow
  • Patent number: 12275757
    Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: April 15, 2025
    Assignees: UNIVERSITY OF WASHINGTON, INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Neil P. King, David Baker, Brooke Fiala, Lance Joseph Stewart, Laurent Perez, Antonio Lanzavecchia, Jessica Marcandalli, Jorge Fallas, Yang Hsia
  • Patent number: 12274743
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: August 12, 2024
    Date of Patent: April 15, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • Patent number: 12269846
    Abstract: The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: April 8, 2025
    Inventor: Swey-Shen Chen
  • Patent number: 12263214
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: April 1, 2025
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • Patent number: 12257302
    Abstract: The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: March 25, 2025
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Hugh Mason, Andrew Diamos, Mary Pardhe, Brandon Favre
  • Patent number: 12258572
    Abstract: This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: March 25, 2025
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Michael A. Barry
  • Patent number: 12251434
    Abstract: The present invention provides a target sequence of an RNA virus. The target sequence is a nucleic acid sequence fragment in the gene sequence in the RNA virus containing 20-40 bases and having not less than 95% similarity to genome sequence of human or related species such as livestock and poultry. The above-mentioned target sequence of the RNA virus is selected from SEQ ID NO. 1-SEQ ID NO. 615. The present invention also relates to a primer composition for constructing the above-mentioned target sequence, biomaterials such as antisense RNA related to the above-mentioned target sequence, and related uses such as design of a vaccine lacking the target sequence. The virus fragment with the above-mentioned sequence constructed in the present invention has the function of interacting with human genomic DNA and is similar to viral miRNA.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: March 18, 2025
    Assignees: SHANGHAI PUBLIC HEALTH CLINICAL CENTER, Shanghai Yizhe Biotechnology Co., Ltd.
    Inventors: Wenqiang Yu, Zhenyan Li, Jianqing Xu, Hailin Wang, Wei Li, Cheng Lian, Peng Xu
  • Patent number: 12247056
    Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.
    Type: Grant
    Filed: March 4, 2024
    Date of Patent: March 11, 2025
    Assignee: Othair Prothena Limited
    Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
  • Patent number: 12240886
    Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class I molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises ?1, ?2, ?3 and ?2m domains.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: March 4, 2025
    Assignee: University Health Network
    Inventors: Naoto Hirano, Munehide Nakatsugawa, Muhammed Aashiq Rahman, Kenji Murata
  • Patent number: 12234260
    Abstract: A Hepatitis E virus (HEV)-based virus like nanoparticle (HEVNP) made with a modified capsid protein containing at least a portion of open reading frame 2 (ORF2) protein conjugated with gold nanocluster is provided. Also provided are methods of targeted delivery of a nucleic acid using the HEVNP.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: February 25, 2025
    Assignee: The Regents of the University of California
    Inventors: R. Holland Cheng, Chun Chieh Chen, Mohammad Ali Baikoghli, Marie Stark
  • Patent number: 12233123
    Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: February 25, 2025
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Megan Ermler, Florian Krammer
  • Patent number: 12215348
    Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: February 4, 2025
    Assignee: Juno Therapeutics, Inc.
    Inventors: Mirna Mujacic, Ayu Rahardjo
  • Patent number: 12209291
    Abstract: Embodiments disclosed include systems, devices, and methods for analysis of samples containing particles used for gene delivery to determine a quality of the sample and/or an indication that the gene delivery particles are in a full, partial, and/or empty state. The present disclosure also relates to determining a protein and/or NA content in samples with known proportions of gene delivery particles in a full, partial, and/or empty state and based on the determination, establish a relationship between NA content and proportions of gene delivery particles in a full state. The present disclosure also relates to using such an established relationship to predict a proportion of the gene delivery particles in a full, partial, and/or empty state in test samples having the gene delivery particles in an unknown state.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: January 28, 2025
    Assignee: ProteinSimple
    Inventors: Jiaqi Wu, Christopher Heger
  • Patent number: 12202862
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: January 21, 2025
    Assignee: MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • Patent number: 12194157
    Abstract: According to some embodiments, a method of providing treatment of a host comprises binding a carrier to cell structures of cells of the host to reduce a likelihood of an agent binding to said cell structures to at least partially inhibits the agent from binding to said cell structures, wherein the carrier comprises a core and a surface functionalized on the core, wherein the functionalized surface bind to target areas of cell structures of the host's cells, and wherein the carrier is to be used as targeted treatment for one or more disease, infections or allergic reactions caused by a disease-causing agent or source.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: January 14, 2025
    Assignee: FINNCURE OY
    Inventor: Erik Johan Niemelä
  • Patent number: 12195499
    Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: September 7, 2023
    Date of Patent: January 14, 2025
    Assignee: Gliknik Inc.
    Inventors: David S. Block, Emmanuel Y. Merigeon, Henrik Olsen